Oropouche was first isolated in Trinidad in 1955: the first 2026 Ann Afr Med review reframes it as a three-continent threat

Oropouche virus was first isolated in Trinidad and Tobago in 1955. By 2026, it has produced documented outbreaks in Brazil, Colombia and Peru, with severe fetal outcomes including microcephaly following vertical transmission in pregnant women infected during the recent Acre and broader Brazilian waves. A 1 July 2026 review in the Annals of African Medicine, written by a four-author clinical team led by Saurabh Agarwal of Government Medical College Surat, reframes the virus as a three-continent threat rather than an Americas-endemic curiosity, and ties the clinical picture to a transmission cycle that depends primarily on a biting midge rather than a mosquito. That detail changes what the rest of the world's surveillance and protection layers need to look like.

What the review covers

The paper is a clinical review for a general medical reader, organised around virology, transmission, clinical features, diagnostics and prevention. It opens by placing Oropouche in the Simbu group of Orthobunyaviruses, with three single-stranded negative-sense RNA segments and a spherical lipid envelope. It then walks the transmission cycle, the geographic spread since 1955, the clinical spectrum from mild febrile illness through meningitis, the differential-diagnosis problem with dengue and chikungunya, and the still-active vaccine development pipeline.

The structural framing the authors adopt is the one that has been missing from most consumer and institutional coverage of Oropouche until now. Oropouche is not an Aedes-borne arbovirus in the way dengue, Zika, chikungunya and yellow fever are. Its primary vector is Culicoides paraensis, a biting midge of the family Ceratopogonidae, with Culex quinquefasciatus as a secondary vector. The midge is orders of magnitude smaller than a mosquito, can pass through standard insect screens, and has activity patterns that do not track neatly to dawn and dusk. Reading Oropouche through a dengue-style protection lens is the standard mistake.

The three-continent reframing

The Americas story is the load-bearing one. Oropouche first appeared in Trinidad in 1955, then reappeared in Brazil, Colombia and Peru in subsequent decades, with the largest documented outbreaks concentrated in the Amazon basin. The recent Brazilian outbreaks, including the documented Acre cluster, brought two new pieces of evidence into the institutional record: severe fetal outcomes including microcephaly and congenital anomalies following vertical transmission in pregnant women, and a clinical overlap with dengue and chikungunya severe enough to require laboratory confirmation for case ascertainment.

The African reframing sits on three pieces of evidence the review assembles. First, the Simbu group of orthobunyaviruses, of which Oropouche is the load-bearing human pathogen, has documented relatives circulating in Africa. Second, the vector ecology of Culicoides paraensis and related midges is pan-tropical, including rainforest and peri-urban West Africa. Third, the diagnostic asymmetry between suspected dengue, suspected chikungunya, and suspected Oropouche in Africa means that Oropouche cases, where they exist, are being classified as something else. The review does not claim that Oropouche is currently established in Africa; it claims that the clinical surveillance architecture cannot distinguish Oropouche from dengue and chikungunya with the tools most African health systems have at the front line. That is the framing Africa needs to hear.

The third continent is the one the European and North American reader sits on. The 2024 European travel-imported cluster, and the parallel US travel-imported cases, are the basis for the authors' claim that Oropouche is no longer an export story that stays in the exporting country. The travel-imported case is the connective tissue between the Americas reservoir and the institutional readiness of importing countries.

The clinical spectrum, and why diagnosis is hard

The clinical spectrum runs from a cold-like febrile illness through to meningitis. Headache, myalgia, arthralgia and photophobia are the canonical features, with a small fraction of cases progressing to neurological involvement. The vertical transmission signal, with documented microcephaly and congenital anomalies in infants born to women infected during pregnancy, is the clinically most consequential feature for the European and North American reader. It is also the feature that places Oropouche alongside Zika in the small group of arboviruses with documented teratogenic potential.

The diagnostic problem is structural. The early clinical picture overlaps with dengue and chikungunya to the point that laboratory confirmation is required to distinguish them. The review details the two-track diagnostic approach: serology (IgM detection, paired acute-convalescent samples) and molecular methods (nested reverse-transcriptase PCR, viral isolation, immunofluorescence). The molecular tools are concentrated in reference laboratories. The serological tools cross-react with other Simbu-group orthobunyaviruses, which limits their specificity in Africa where related viruses circulate. The result is a diagnostic architecture in which Oropouche is detectable but not routinely looked for.

The protection layer that actually works against midges

The midge-driven transmission cycle does not respect the protection layer that the European and North American reader has been trained to use against Aedes mosquitoes. Standard 1.2 mm mosquito mesh does not reliably exclude Culicoides paraensis; the midges pass through gaps that exclude mosquitoes. Insecticide-treated bed nets are effective only if the mesh is fine enough (around 0.6 mm or smaller) and intact. Permethrin-based repellents and clothing treatments retain activity against midges in published entomological studies, although the evidence base is thinner than the equivalent evidence base for Aedes mosquitoes.

The daytime activity profile adds a second layer of complexity. Culicoides paraensis bites during daylight hours in shaded forest-edge environments, not just at dawn and dusk. The standard Aedes protection advice (avoid dawn and dusk, wear long sleeves in the evening, sleep under a net) does not capture the midge exposure window. Source reduction, which is the load-bearing intervention against container-breeding Aedes, does not work against midges because midges breed in soil, manure and rotting vegetation rather than in artificial containers. The protection layer that works against Oropouche is closer to the personal-protection layer that works against sandflies in Mediterranean Europe: fine-mesh netting, treated clothing, daytime vigilance in shaded vegetation, and repellent on exposed skin.

What to watch across the rest of 2026

Three signals will tell the institutional reader whether the Agarwal review's three-continent framing is holding. First, the next ECDC and PAHO Oropouche situation updates: the European travel-imported case count from 2024 is the baseline, and any 2025-2026 increase will track whether Europe is seeing more introductions or better detection. Second, whether the Brazilian vertical-transmission evidence base expands beyond the Acre cluster: the teratogenic signal is the most consequential clinical finding, and a wider geographic spread would convert the Brazilian signal into a continental signal. Third, whether the WHO Oropouche fact sheet, last updated in 2024, picks up the African reframing in a 2026 revision: institutional recognition of the three-continent framing is the structural reason this review matters.

What we know

• Oropouche virus (OROV) is a Simbu-group orthobunyavirus with three single-stranded negative-sense RNA segments, first isolated in Trinidad and Tobago in 1955, and has since produced documented outbreaks in Brazil, Colombia and Peru (source: Agarwal et al., Ann Afr Med 2026 Jul 1, PMID 40952812).
• The primary vector is the biting midge Culicoides paraensis, with Culex quinquefasciatus as a secondary vector; the midge is far smaller than a mosquito and can pass through standard insect screens (source: Agarwal et al., Ann Afr Med 2026, PMID 40952812).
• The recent Brazilian outbreaks, including Acre, have produced documented severe fetal outcomes including microcephaly and congenital anomalies following vertical transmission in pregnant women (source: Agarwal et al., Ann Afr Med 2026, PMID 40952812).
• The clinical picture overlaps with dengue and chikungunya; laboratory confirmation by serology (IgM) and molecular methods (nested RT-PCR, viral isolation, immunofluorescence) is required for case ascertainment (source: Agarwal et al., Ann Afr Med 2026, PMID 40952812).
• Travel-imported OROV cases have been documented in the United States and Europe, the structural reason the 2024 ECDC and US CDC travel advisories were issued (source: Agarwal et al., Ann Afr Med 2026, PMID 40952812; ECDC Oropouche virus disease fact sheet).

Sources cited

1. Agarwal S, Gupta V, Gupta A, Singh B, Jain R. A New Threat on the Rise: Oropouche Viral Infection. Annals of African Medicine 2026 Jul 1;25(4):753-759. DOI 10.4103/aam.aam_199_25. PMID 40952812. https://pubmed.ncbi.nlm.nih.gov/40952812/
2. Pan American Health Organization. Oropouche virus fact sheet and epidemiological updates. https://www.paho.org/en/oropouche
3. European Centre for Disease Prevention and Control. Oropouche virus disease fact sheet (covering the 2024 European travel-imported cluster). https://www.ecdc.europa.eu/en/oropouche-virus-disease
4. World Health Organization. Oropouche virus disease fact sheet. https://www.who.int/news-room/fact-sheets/detail/oropouche-virus-disease
   Published 2026-07-01 · Mosticare Editorial